4th Induced Proximity-Based Drug Discovery Summit

Kongressthemen
Whilst PROTACs continue to make headwind, much of the heterobifunctional and monovalent opportunity beyond the ubiquitin proteosome system remains untapped, drawing in new and distinguished biopharma in the race to develop new stabilization, modulation, post-translational modification, and inactivation/activation modalities.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
URL:
Brochure: https://go.evvnt.com/2313820-3?pid=4832

Speakers: Andrew Zhang, Director, Chemical Biology, AstraZeneca, Brandon Turunen, Co-Founder and Chief Technology Officer, Solu Therapeutics and More.

https://go.evvnt.com/2313820-2?pid=4832

Frau Isabella Hunter